Kelyniam Global Reports 2025 Financial Results

Published: Monday, March 16, 2026 at 4:01 am

Kelyniam Global Reports 2025 Financial Results, Announces FDA Clearance and Rejects Acquisition Interest

Kelyniam Global, a company specializing in custom cranial implants, has released its financial results for the year ending December 31, 2025. The company reported a net loss of $138,555, representing an 85% improvement compared to the previous year's net loss of $920,206. This improvement was attributed to a strong second-half performance and effective expense management.

Total revenue for the year was $3,053,222, an 8% decrease from $3,328,384 in 2024. Despite the revenue dip, the company saw a solid recovery in the latter half of the year. Gross profit was $2,387,283, down from $2,594,137. The company reported an operating loss of $(96,449), a shift from the operating income of $277,037 in the prior year. EBITDA was $(81,661), compared to $322,824.

In a significant development, Kelyniam Global secured FDA 510(k) clearance for its Fusion cranial and craniofacial implants. These implants utilize a novel biomaterial, VESTAKEEP Fusion, which combines PEEK with biphasic calcium phosphate (BCP). This innovative material aims to enhance bone cell attachment and promote bone regrowth. The Fusion implants also feature a patented integrated fixation system and can be delivered within 24-48 hours.

Furthermore, the company disclosed that it received unsolicited interest from a third party regarding a potential acquisition in late 2025. However, after careful evaluation, the board of directors determined that the proposed offer was undervalued and did not reflect the company's full potential. Consequently, Kelyniam Global decided not to pursue further discussions. The company stated its commitment to evaluating opportunities that align with its long-term strategy and enhance shareholder value.

BNN's Perspective:

While the revenue dip is concerning, the significant improvement in net loss and the FDA clearance for the Fusion implants are positive signs. The company's focus on innovation and its rejection of the acquisition offer suggest a belief in its long-term growth prospects. Investors should closely monitor the company's ability to translate its technological advancements into sustained revenue growth.

Keywords: Kelyniam Global, financial results, cranial implants, FDA clearance, Fusion implants, VESTAKEEP Fusion, PEEK, BCP, net loss, revenue, acquisition interest, craniofacial implants, biomaterial, medical devices, custom implants

Full Story